Drug Database
DT

DTwP-HB-Hib vaccine (Pentavac SD, SSI / Pentavac PFS, SSI)

✓ Approved

Serum Institute of India Pvt. Ltd. · Vaccine · Vaccine

What is DTwP-HB-Hib vaccine?

DTwP-HB-Hib vaccine is a vaccine developed by Serum Institute of India Pvt. Ltd.. It is approved for therapeutic indications via injectable (others) or intramuscular (im) injection.

Drug Profile

Brand NamesPentavac SD, SSI, Pentavac PFS, SSI
CompanySerum Institute of India Pvt. Ltd.
Drug ClassVaccine
RouteInjectable (Others), Intramuscular (IM) Injection
StatusApproved
Sources: ClinicalTrials.gov, Serum Institute of India Pvt. Ltd.

Therapeutic Indications

DTwP-HB-Hib vaccine is developed for 4 unique indications across 1 therapeutic area.

Therapeutic AreaConditionPhase
Infections and infestationsDiphtheria✓ Approved
Infections and infestationsHepatitis B✓ Approved
Infections and infestationsPertussis✓ Approved
Infections and infestationsTetanus✓ Approved

Related Research Articles

PubMedAAPS PharmSciTech2026-09-19

Comprehensive Stability Assessment of Squalene in a Nanoemulsion Adjuvant and the SpiN-Tec Vaccine: HPLC Quantification, Stress Testing, and Stability Studies.

Gomes Isabela Pereira IP, Rivelli Graziella Gomes GG, Bagno Flávia Fonseca FF, Hojo-Souza Natália Satchiko NS et al.

Squalene-based nanoemulsions are widely used as adjuvants in vaccine formulations, but their stability can be affected by environmental factors such as pH, oxidative stress, temperature, and light. We have produced a squalene nanoemulsion (CTVad1) to support the clinical development of new vaccines. This study aimed to develop and validate an HPLC method for squalene quantification in SpiN-Tec, a recombinant protein vaccine against COVID-19. We also aimed to evaluate the stability of the CTVad1 adjuvant and SpiN-Tec under controlled storage conditions. A reversed-phase HPLC method was developed and validated, and comprehensive forced degradation studies were performed on the raw material and SpiN-Tec under acidic, basic, oxidative, thermal, and photolytic conditions to demonstrate the stability-indicating capability of the method. Physicochemical, morphological, and biological characteristics were assessed, and stability studies of both the vaccine and the CTVad1 adjuvant were performed under accelerated and long-term conditions. The HPLC method was selective, precise, accurate, linear, and robust. Squalene raw material degraded under all tested conditions, whereas formulation in nano-sized globules improved its stability, with degradation observed only under hydrogen peroxide and light exposure. CTVad1 remained stable over time, exhibiting only minor, non-critical changes within the specification limits in both accelerated and long-term stability studies, regardless of the glass packaging used (clear or amber). In addition, the SpiN-Tec vaccine maintained its physicochemical and biological integrity under all tested conditions, with all evaluated parameters remaining within the established specification ranges. Our findings demonstrate that proper formulation, packaging, and storage conditions can preserve squalene stability in nanoemulsion-based vaccines, ensuring the quality, safety, and efficacy of the SpiN-Tec vaccine and its adjuvant throughout shelf life.

PMID 42760453
Read full article →
PubMedOcular immunology and inflammation2026-09-19

Bilateral Maculopathy in an Infant Following Measles, Mumps, Rubella, and Varicella-Zoster (MMRV) Vaccination.

Ben-Avi Ravid R, Amer Radgonde R

To report on the long-term clinical outcome of a healthy infant who presented with posterior uveitis following the administration of the combined measles, mumps, rubella, and varicella (MMRV) vaccine. Descriptive case report. A 13-month-old infant presented with bilateral visual loss two weeks after receiving the MMRV vaccine. Ophthalmic examination revealed bilateral retinitis and retinal vasculitis with exudative retinal detachment. Extensive infectious work-up was conducted including serologic exams and PCR testing of blood, aqueous humor, cerebrospinal fluid and urine. Serological tests for measles yielded positive IgM and IgG titers. PCR testing for measles in the aqueous humor and urine was negative. Neurologic assessment and neuroimaging were unremarkable, excluding central nervous system involvement. Empiric systemic antiviral and corticosteroid therapy was initiated. Gradual resolution of posterior uveitis ensued, culminating in bilateral macular scars. Over a six-year follow-up period, the patient demonstrated stable ocular findings with no evidence of recurrent inflammation or systemic autoimmune disease. Final visual acuity was 6/9 in each eye. This case represents a rare occurrence of non-necrotizing retinitis following MMRV vaccination. To our knowledge, this is the first report describing the sequential OCT characteristics of presumed measles vaccine-associated retinitis. The prolonged follow-up period supports the absence of an alternative etiology and provides valuable insight into the long-term course and visual prognosis of vaccine-associated retinopathy.

PMID 42760840
Read full article →
PubMedMedScience2026-09-19

Neoantigen cancer vaccines for gastrointestinal tumors: opportunities and challenges.

Zhao Zixuan Z, Du Xinyu X, Gao Xiaoliang X, Zhao Sheng S et al.

Gastrointestinal tumors are characterized by high global incidence and mortality rates. Although immune checkpoint inhibitors (ICIs) have achieved breakthroughs in some of these cancers, their overall response rate remains low. Neoantigen cancer vaccines have emerged as a promising new strategy for immunotherapy in gastrointestinal tumors due to their high specificity and strong immunogenicity. These vaccines effectively activate specific T-cell immunity and can produce synergistic effects when combined with ICIs. Various vaccine platforms offer distinct advantages, and clinical trials have shown encouraging potential in inducing immune responses and extending progression-free survival. Meanwhile, current challenges and future directions cannot be ignored. Key challenges primarily involve the accuracy of neoantigen prediction, tumor heterogeneity, and optimal treatment timing. Future directions include artificial intelligence (AI)-assisted multi-omics screening, the development of universal vaccines, optimization of novel delivery systems, and multimodal combination strategies. These advances are expected to promote the application of neoantigen cancer vaccines in postoperative recurrence prevention and early-stage treatment, ultimately moving toward personalized precision immunotherapy. This article systematically reviews the clinical progress and prospects of neoantigen cancer vaccines in treating gastrointestinal tumors, aiming to provide insights for immunotherapy in this field and offer new perspectives for further optimization of such vaccines.

PMID 42760419
Read full article →
PubMedAdvanced materials (Deerfield Beach, Fla.)2026-09-18

Bio-hybrid Nanostructures Orchestrate Photodynamic Remodeling of the Fusobacterium nucleatum-Associated Colorectal Tumor Niche.

Tao Maliang M, Wei Binbin B, Yang Ye Y, Zou Hang H et al.

The intratumoral microbiota acts as a microbial immune checkpoint in colorectal cancer (CRC), yet current strategies either kill silently without immune activation or permit bacterial rebound through incomplete targeting. Here we report a bio-hybrid assembly designed to synchronize the eradication of CRC cells and their tumor-associated Fusobacterium nucleatum. This system integrates a hemoglobin (Hb)-augmented aggregation-induced emission (AIE) photosensitizing module into cRGD-functionalized ginger-derived vesicles. This architecture couples Hb-associated oxygen availability with molecular confinement of the photosensitizer while harnessing the intrinsic anti-inflammatory components of the plant carrier to mitigate off-target toxicity. Light activation initiates a dual cascade: it induces lysosomal pyroptosis in malignant cells and disrupts key F. nucleatum pathways related to membrane transport and DNA repair. This synchronized killing elicits the coordinated release of damage- and pathogen-associated molecular patterns (PAMPs), effectively transforming an immunologically cold tumor into a robust in situ vaccine that drives dendritic cell maturation and systemic T-cell immunity. Our findings demonstrate that the integration of natural bioactivity with supramolecular engineering provides a biocompatible strategy for coordinated tumor-bacterial disruption and immunogenic remodeling of the F. nucleatum-associated tumor niche in CRC.

PMID 42755172
Read full article →
PubMedFrontiers in systems biology2026-09-18

Innate immune activation profiles are associated with polarization of the T cell response to recombinant arenaviral vectors.

Szaffich Sarah S, Just Valentin V, Cvetkovic Natalija N, Pepic Naila N et al.

Arenavirus-based vectors are uniquely positioned to generate durable T cell responses against tumors, which remains a central challenge in cancer immunotherapy. Two members of the arenavirus family, Lymphocytic choriomeningitis virus and Pichinde virus, were genetically engineered to encode a non-oncogenic fusion protein, originating from human papillomavirus 16 E6 and E7. Hereafter, these vectors are referred to as HB-201 and HB-202, respectively. HB-201 alone or in combination with HB-202 elicited strong and durable E6/E7-specific CD8+ T cell responses in HPV 16+ cancer patients. Despite their classification within the same virus family, Lymphocytic choriomeningitis virus and Pichinde virus are phylogenetically distant, which may influence virus-host interactions and the pathways leading to antiviral immune responses. Previous studies showed that both vectors infect and activate professional antigen presenting cells. To elaborate on these findings, this study aimed to characterize in depth the innate immune response to HB-201 and HB-202 by single cell sequencing in an in vitro human PBMCs infection model. We confirmed the preferential infection of antigen presenting cells for both vectors, with HB-201 infecting the cross-priming conventional dendritic cell subset cDC1 more efficiently than HB-202. Furthermore, HB-201 induced stronger type I interferon responses than HB-202, as well as quantitative and qualitative differences in inflammatory response associated with a distinct reshaping of monocyte subsets towards intermediate and non-classical monocytes. Antigen presentation and T cell priming cytokines in dendritic cells appeared to favor antiviral CD8+ T cell responses upon HB-201 infection, whereas a more balanced CD4+ and CD8+ priming profile was observed upon HB-202 infection. Immunogenicity data from patients treated with HB-201 and HB-202 confirmed the in vitro findings with functional differences in early T cell response. Thus, despite their shared origins within the arenavirus family, HB- 201 and HB-202 demonstrate distinct differences in early host-virus interaction, potentially resulting in shaping unique T cell responses.

PMID 42755684
Read full article →
PubMedClinical medicine insights. Case reports2026-09-18

Splenic Sequestration and Suspected Transient Aplastic Crisis in Sickle-Cell SC/Hemoglobin-G Disease in an Adult: A Case Report.

Patel Evani E, Gunter Simon S, Hartner Lee L

Acute Splenic Sequestration Crisis (ASSC) and Transient Aplastic Crisis (TAC) are severe, but distinct, hematologic complications of sickle cell disease (SCD). ASSC typically presents with acute splenomegaly and anemia due to red blood cell (RBC) pooling, while TAC, often secondary to Parvovirus B19 infection, results in a sudden halt in erythropoiesis and reticulocytopenia. The concurrence of these two conditions is rare, particularly in adults and non-Hb-SS genotypes. We describe a 36-year-old woman with Hb-SC and Hb-G Philadelphia variant SCD who presented with non-specific symptoms who was found to have marked splenomegaly and laboratory findings of severe anemia (hemoglobin 3.8 g/dL), thrombocytopenia, and reticulocytopenia. These combined findings raised concern for ASSC with suspected TAC, especially in light of her positive Parvovirus B19 IgM antibodies. We describe the importance of having a structured and precise diagnostic work-up to elucidate differences between the two conditions in the absence of a bone marrow biopsy, and the rarity of concurrent ASSC with presumed TAC in a patient with Hb-SC SCD. Our case highlights that early recognition of overlapping sickle cell complications despite a bone marrow biopsy is critical as it led to timely diagnosis, optimized management strategies, and reduced morbidity.

PMID 42756401
Read full article →

+9996 more articles available with a free account

Sign up free to view all articles →

Ask about DTwP-HB-Hib vaccine